1. The Utility of Digital Anal Rectal Examinations in a Public Health Screening Program for Anal Cancer
- Author
-
Gary M. Clifford, Elizabeth Y. Chiao, Gypsyamber D'Souza, Elizabeth A. Stier, and Alan G. Nyitray
- Subjects
Male ,mass screening ,medicine.medical_specialty ,anal cancer ,media_common.quotation_subject ,MEDLINE ,DARE ,men who have sex with men ,World Health Organization ,Men who have sex with men ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Screening HPV Assoc Conditions ,medicine ,Humans ,Anal cancer ,Homosexuality ,Homosexuality, Male ,Early Detection of Cancer ,Mass screening ,anal neoplasms ,media_common ,030219 obstetrics & reproductive medicine ,business.industry ,Public health ,HIV ,Obstetrics and Gynecology ,Digital Anal Rectal Examination ,General Medicine ,Anus Neoplasms ,medicine.disease ,Critical appraisal ,030220 oncology & carcinogenesis ,Family medicine ,Practice Guidelines as Topic ,business ,Anal rectal - Abstract
Objectives There are no uniform screening recommendations for anal cancer. Medical practice guidelines are now available on the use of Digital Anal Rectal Examinations (DARE) for the detection of anal cancer; however, because screening can result in more harm than benefit, our objective was to assess the evidence for use of DARE as a public health screening tool. Materials and methods We conducted a current critical appraisal of anal cancer literature using World Health Organization criteria for assessing the potential utility of a public health screening program. Results Digital Anal Rectal Examination satisfies most, but not all, World Health Organization criteria for a public health program that seeks to detect early invasive anal cancer in populations at high risk for anal cancer, most notably HIV-positive men who have sex with men; however, DARE is not appropriate when facilities for treatment are nonexistent. In addition, there are insufficient data on DARE sensitivity and specificity. Conclusions The mildly invasive nature of DARE, limited likelihood of adverse procedure-related events, cost-effectiveness and patient acceptability, as well as wide availability of DARE support consideration of its integration into screening for populations at high risk of anal cancer, especially HIV-positive men who have sex with men.
- Published
- 2020
- Full Text
- View/download PDF